Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NF- kappa B2/p100 induces Bcl-2 expression.

P Viatour1, M Bentires-Alj, A Chariot

  • 1Center for Cellular and Molecular Therapy, University of Liège, Liège, Belgium.

Leukemia
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Reactivation of Multipotency in the Mammary Gland - a Ripple in the Pond and a Turn of the Tide.

Journal of mammary gland biology and neoplasia·2025
Same author

Kaposi sarcoma and Kaposi inflammatory cytokine syndrome following allogeneic haematopoietic stem cell transplantation: A case report.

British journal of haematology·2025
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

ESMO open·2023
Same author

Editorial Expression of Concern: Restoration of SHIP-1 activity in human leukemic cells modifies NF-jB activation pathway and cellular survival upon oxidative stress.

Oncogene·2023
Same journal

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026
Same journal

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same journal

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026
Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026
Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026
Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026
See all related articles

Nuclear factor kappaB (NF-kappaB) pathway activation, specifically involving NF-kappaB2/p100 and Bcl-3, promotes Bcl-2 expression. This suggests NF-kappaB2/p100 is a key regulator of Bcl-2 in cancer cells.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • Nuclear factor kappaB (NF-kappaB) signaling is crucial for cell survival and implicated in cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
  • NF-kappaB2/p100 and bcl-3 genes are linked to chromosomal translocations in these hematologic malignancies.
  • NF-kappaB activation confers resistance to apoptosis in cancer cells.

Purpose of the Study:

  • To investigate the role of the NF-kappaB transcription factor in regulating the expression of the antiapoptotic protein Bcl-2.
  • To determine if NF-kappaB directly modulates Bcl-2 gene expression and identify the specific mechanisms involved.

Main Methods:

  • Bcl-2 promoter analysis to identify potential NF-kappaB binding sites.
  • Transfection assays using bcl-2 promoter constructs in HCT116 cells to assess NF-kappaB transactivation.

Related Experiment Videos

  • Investigating the interaction of NF-kappaB subunits (p50, p52) and Bcl-3 with the bcl-2 promoter.
  • Overexpression studies of NF-kappaB2/p100 in MCF7AZ breast cancer cells.
  • Correlation analysis of NF-kappaB2/p100 and Bcl-2 expression in breast cancer and CLL cells.

    • Main Results:

    • Bcl-2 promoter contains multiple putative NF-kappaB binding sites.
    • NF-kappaB was confirmed to transactivate the bcl-2 promoter in HCT116 cells.
    • A specific kappaB site at -180 was identified, bound and transactivated by p50 or p52 homodimers.
    • p50/p52 homodimers transactivate the bcl-2 promoter via association with Bcl-3.
    • Overexpression of NF-kappaB2/p100 and its processed form p52 induced endogenous Bcl-2 expression in MCF7AZ cells.
    • High NF-kappaB2/p100 expression correlated with high Bcl-2 expression in breast cancer and CLL cells.

    Conclusions:

    • Bcl-2 is a direct target gene of the NF-kappaB pathway, specifically regulated by NF-kappaB2/p100.
    • The NF-kappaB2/p100-Bcl-3 complex plays a significant role in transactivating the bcl-2 promoter.
    • These findings highlight a novel mechanism by which NF-kappaB2/p100 contributes to cancer cell survival by upregulating Bcl-2.